Tracers / [225Ac]Ac-DOTA-4AH29

[225Ac]Ac-DOTA-4AH29

Also written as [Ac-225]Ac-DOTA-4AH29

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 2

Preclinical only, no clinical indication yet Fibroblast activation / tumour stroma

What it is

Compound class: FAP-targeting single-domain antibody (sdAb) conjugated to DOTA chelator
Target / mechanism: Fibroblast activation protein (FAP)-targeting single-domain antibody PMID 41688618
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	—	DOTA-4AH29	41688618 2026 EJNMMI Res sdAb 4AH29 was radiolabeled with 111In, 177Lu, and 225Ac at a selected pH for 30 min at 50 °C, then purified using NAP5 SEC
—	—	—	—	—	4AH29	42364406 2026 Nucl Med Biol

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-4AH29, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41688618: 'DOTA-4AH29'.